TW279802B - - Google Patents
Info
- Publication number
- TW279802B TW279802B TW081107168A TW81107168A TW279802B TW 279802 B TW279802 B TW 279802B TW 081107168 A TW081107168 A TW 081107168A TW 81107168 A TW81107168 A TW 81107168A TW 279802 B TW279802 B TW 279802B
- Authority
- TW
- Taiwan
- Prior art keywords
- riboflavin
- immunopotentiating
- animals
- safe
- human
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/12—Heterocyclic compounds containing pteridine ring systems containing pteridine ring systems condensed with carbocyclic rings or ring systems
- C07D475/14—Benz [g] pteridines, e.g. riboflavin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP26128891 | 1991-09-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW279802B true TW279802B (zh) | 1996-07-01 |
Family
ID=17359726
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW081107168A TW279802B (zh) | 1991-09-13 | 1992-09-10 |
Country Status (11)
Country | Link |
---|---|
US (2) | US5814632A (zh) |
EP (2) | EP1086696A3 (zh) |
AT (1) | ATE202933T1 (zh) |
AU (1) | AU671421B2 (zh) |
CA (1) | CA2118792C (zh) |
DE (1) | DE69231936T2 (zh) |
ES (1) | ES2157906T3 (zh) |
MY (1) | MY110518A (zh) |
NZ (1) | NZ244270A (zh) |
TW (1) | TW279802B (zh) |
WO (1) | WO1993005784A1 (zh) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9321558D0 (en) * | 1993-10-19 | 1993-12-08 | Radopath Ltd | Anti-viral agents |
GB2319474A (en) * | 1993-10-19 | 1998-05-27 | Radopath Ltd | Anti-viral agents |
IT1306141B1 (it) * | 1999-05-17 | 2001-05-30 | Giampiero Valletta | Composizione per il trattamento del prurito uremico e di forme diprurito non riconducibili a lesioni organiche. |
US6268120B1 (en) * | 1999-10-19 | 2001-07-31 | Gambro, Inc. | Isoalloxazine derivatives to neutralize biological contaminants |
US7985588B2 (en) | 2000-06-02 | 2011-07-26 | Caridianbct Biotechnologies, Llc | Induction of and maintenance of nucleic acid damage in pathogens using riboflavin and light |
US7648699B2 (en) | 2000-06-02 | 2010-01-19 | Caridianbct Biotechnologies, Llc | Preventing transfusion related complications in a recipient of a blood transfusion |
TW590780B (en) | 2000-06-02 | 2004-06-11 | Gambro Inc | Additive solutions containing riboflavin |
US9044523B2 (en) | 2000-06-15 | 2015-06-02 | Terumo Bct, Inc. | Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light |
US6548241B1 (en) | 2000-11-28 | 2003-04-15 | Gambro, Inc. | Storage solution containing photosensitizer for inactivation of biological contaminants |
ATE442143T1 (de) * | 2001-03-21 | 2009-09-15 | Eisai R&D Man Co Ltd | Reduziertes vitamin b2 enthaltende arzneimittel |
US7235392B2 (en) * | 2001-12-07 | 2007-06-26 | The Ohio State University Research Foundation | Apoptotic EBV-transformed lymphocytes, a therapeutic agent for post-transplant lymphoproliferative disorder |
WO2003054150A2 (en) * | 2001-12-07 | 2003-07-03 | The Ohio State University Research Foundation | Apoptotic ebv-transformed lymphocytes, a therapeutic agent for post-transplant lymphoproliferative disorder |
JPWO2003075935A1 (ja) * | 2002-03-11 | 2005-06-30 | エーザイ株式会社 | リボフラビン系化合物を含む医薬 |
AU2003227475A1 (en) * | 2002-04-09 | 2003-10-20 | Eisai Co., Ltd. | Drug containing riboflavin compound |
CA2492103A1 (en) * | 2002-05-10 | 2004-05-27 | The Ohio State University | Flavin n-oxides: new anti-cancer agents and pathogen eradication agents |
JP5430927B2 (ja) | 2006-03-15 | 2014-03-05 | サントリーホールディングス株式会社 | リボフラビンとセサミン類とを含有する組成物 |
SG179481A1 (en) | 2007-03-15 | 2012-04-27 | Suntory Holdings Ltd | Anti-fatigue agent |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1360228A (en) * | 1971-07-30 | 1974-07-17 | Takeda Yakuhin Kk | Veterinary antibiotic preparations |
US4219545A (en) * | 1979-03-23 | 1980-08-26 | Collins Calvin E | Treatment of infectious keratoconjunctivitis in animals |
EP0125252A1 (de) * | 1982-11-16 | 1984-11-21 | MOTSCHAN, Georges | Neue verwendung eines einzelnen vitamins oder einer kombination verschiedener vitamine |
US4708952A (en) * | 1985-02-06 | 1987-11-24 | Aida Salatinjants | Method of treatment of the infectious and viral diseases by one time interference |
AU587863B2 (en) * | 1985-10-07 | 1989-08-31 | Basf Aktiengesellschaft | Vitamin-containing granules and production thereof |
US4871550A (en) * | 1986-09-05 | 1989-10-03 | Millman Phillip L | Nutrient composition for athletes and method of making and using the same |
FI892006A (fi) * | 1988-04-29 | 1989-10-30 | Phil Gold | Lactalbumin saosom tillaeggsaemne i mat. |
JPH02265458A (ja) * | 1989-04-04 | 1990-10-30 | Nikken Food Kk | 老化制御食品 |
US5000888A (en) * | 1990-05-23 | 1991-03-19 | Basf Corporation | Process for spray drying riboflavin to produce a granulate product having low binder content |
FR2674753B1 (fr) * | 1991-04-02 | 1995-03-10 | Jean Berque | Nouvelles indications therapeutiques, en particulier pour le traitement du sida, d'un medicament deja existant et fabrique a partir d'une molecule denuee de contre-indications et d'effets indesirables. |
JPH05163160A (ja) * | 1991-12-13 | 1993-06-29 | Snow Brand Milk Prod Co Ltd | 免疫低下に伴う感染症の予防及び治療用栄養剤 |
-
1992
- 1992-09-08 NZ NZ244270A patent/NZ244270A/en not_active IP Right Cessation
- 1992-09-09 DE DE69231936T patent/DE69231936T2/de not_active Expired - Lifetime
- 1992-09-09 AT AT92919503T patent/ATE202933T1/de active
- 1992-09-09 EP EP00127264A patent/EP1086696A3/en not_active Withdrawn
- 1992-09-09 WO PCT/JP1992/001146 patent/WO1993005784A1/ja active IP Right Grant
- 1992-09-09 EP EP92919503A patent/EP0679398B1/en not_active Expired - Lifetime
- 1992-09-09 ES ES92919503T patent/ES2157906T3/es not_active Expired - Lifetime
- 1992-09-09 CA CA002118792A patent/CA2118792C/en not_active Expired - Lifetime
- 1992-09-09 AU AU25628/92A patent/AU671421B2/en not_active Ceased
- 1992-09-10 TW TW081107168A patent/TW279802B/zh active
- 1992-09-11 MY MYPI92001628A patent/MY110518A/en unknown
-
1995
- 1995-04-12 US US08/420,632 patent/US5814632A/en not_active Expired - Lifetime
-
1998
- 1998-04-15 US US09/060,329 patent/US5945420A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
ATE202933T1 (de) | 2001-07-15 |
NZ244270A (en) | 1995-07-26 |
EP0679398B1 (en) | 2001-07-11 |
EP1086696A3 (en) | 2004-01-02 |
US5814632A (en) | 1998-09-29 |
US5945420A (en) | 1999-08-31 |
AU2562892A (en) | 1993-04-27 |
EP0679398A1 (en) | 1995-11-02 |
EP0679398A4 (en) | 1994-08-19 |
WO1993005784A1 (en) | 1993-04-01 |
MY110518A (en) | 1998-07-31 |
CA2118792C (en) | 2006-08-22 |
ES2157906T3 (es) | 2001-09-01 |
DE69231936D1 (de) | 2001-08-16 |
EP1086696A2 (en) | 2001-03-28 |
AU671421B2 (en) | 1996-08-29 |
CA2118792A1 (en) | 1993-04-01 |
DE69231936T2 (de) | 2001-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW279802B (zh) | ||
AU5713590A (en) | Medical apparatus having protective lubricious coating | |
AU6067390A (en) | Catheter, manipulator and combination thereof | |
ATE121295T1 (de) | Augentropfenarzneimittel. | |
ZA902520B (en) | Aryl-substituted rhodanine derivatives | |
ZA898440B (en) | Lactamimides in the treatment of drug-resistant protozoal infections | |
AU5060690A (en) | Sterilant mixture and sterilization method | |
AU4574689A (en) | Phenoxy and phenylthio, amino substituted benzocycloalkane derivatives in the treatment and prevention of drug-resistant protozoal infections | |
GB2230449B (en) | Sterilisation or incineration method | |
IL102326A0 (en) | Glycopeptides,a process for their preparation and their use | |
GR3002962T3 (en) | C.12 modified erythromycin a derivatives | |
AU1662092A (en) | Use of a 1,3-oxathiolan derivative for the treatment of hepatitis b infection | |
NZ228023A (en) | 24(r)-scymnol; preparatory processes and pharmaceutical compositions | |
NZ238580A (en) | Pharmaceutical composition comprising cephalosporin and xanthine(s); methods of treatment | |
HU9200025D0 (en) | Medical preparations for treating depression | |
GB2255718B (en) | Pharmaceutical composition for treating bacterial and / or viral infection | |
NZ236734A (en) | Alisamycin, pharmaceutical compositions and actinomycete culture (dsm 5559) | |
GR3005838T3 (zh) | ||
EP0427402A3 (en) | Treatment of shock by cyclodextrins and their derivatives | |
BG96634A (en) | Method for the preparation of antibiotic complex | |
CA2079328A1 (en) | Veterinary formulation of amoxycillin and clavulanic acid, and derivatives thereof | |
IT1248485B (it) | Derivati della 1,4-benzotiazina ad azione immunostimolante e immonomodulatrice |